Gene editing for corneal disease management

Sudhanshu P Raikwar,

Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, United States

Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, United States

Apoorva S Raikwar,

Department of Microbiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, United States

Shyam S Chaurasia,

Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, United States

Rajiv R Mohan

Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, United States

Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, United States

Mason Eye Institute, School of Medicine, University of Missouri, Columbia, MO 65212, United States

Ophthalmology and Molecular Medicine, One-health One-Medicine Ophthalmology and Vision Research, University of Missouri, Columbia, MO 65211, United States

Abstract

Gene editing has recently emerged as a promising technology to engineer genetic modifications precisely in the genome to achieve long-term relief from corneal disorders. Recent advances in the molecular biology leading to the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) and CRISPR-associated systems, zinc finger nucleases and transcription activator like effector nucleases have ushered in a new era for high throughput *in vitro* and *in vivo* genome engineering. Genome editing can be successfully used to decipher complex molecular mechanisms underlying disease pathophysiology, develop innovative next generation gene therapy, stem cell-based regenerative therapy, and personalized medicine for

Correspondence to: Rajiv R Mohan, PhD, FARVO, Professor, Ophthalmology and Molecular Medicine, One-health One-Medicine Ophthalmology and Vision Research, University of Missouri, 1600 E. Rollins Road, Columbia, MO 65211, United States. mohanr@health.missouri.edu Telephone: +1-573-8841449, Fax: +1-573-8844100.

corneal and other ocular diseases. In this review we describe latest developments in the field of genome editing, current challenges, and future prospects for the development of personalized gene-based medicine for corneal diseases. The gene editing approach is expected to revolutionize current diagnostic and treatment practices for curing blindness.

Keywords

INTRODUCTION

According to World Health Organization ocular diseases affect about 285 million people worldwide. It is estimated that over 39 million people suffer from blindness and 246 million people have low or impaired vision worldwide. In the United States, vision impairment is among the top ten disabilities according to the Centers for Disease Control and Prevention. According to the National Eye Institute, approximately 38 million people have vision impairment in the United States with an annual cost of over $68.8 billion for medical care. If the present increasing trend in eye disease continues, it is estimated that by 2050 the patient volume with blindness will increase by 150% with a corresponding increase of 250% in direct medical costs leading to an economic burden of $717 billion. To break this increasing trend and fulfill unmet clinical needs, it is imperative to develop novel next generation gene-based molecular therapies for ocular disease.

Cornea is the transparent tissue in front of the eye. It provides two thirds of refractive power and protection to the eye[1]. Trauma, injury and/or infection to the eye are known to compromise corneal transparency and cause corneal fibrosis and/or neovascularization. Corneal diseases are the second leading cause of blindness globally with an estimated 23 million patients and nearly 80% of all corneal blindness is preventable. Corneal defects are one of the most prevalent reasons for vision impairment worldwide. About 4% of the United States population has corneal disorders and approximately 1.5 million additional people experience corneal blindness each year. It is more pronounced in developing countries especially among children due to trachoma which alone causes blindness in 4.9 million people worldwide[2,3]. The current treatments for corneal blindness offer only short-term relief, require repeated drug application, meticulous patient compliance, cause side effects, and often fail. The surgical corneal transplantation is typically used to restore vision, requiring donor corneas which are not available in many countries, and their availability in America is sharply declining due to laser surgeries, hepatitis, human immunodeficiency virus (HIV), *etc*. Therefore there is an urgent need to develop novel corneal disease models and therapeutic strategies to treat corneal diseases. Over the past several years, the major focus of our research has been on the development of novel strategies for gene therapy to treat corneal diseases using adeno-associated virus (AAV) and nanoparticles[1,4–11]. Our lab has demonstrated that various AAV serotypes could be successfully used to deliver

therapeutic genes to treat corneal diseases with varying transduction efficiency without major side effects. Our ongoing research suggests that AAV and nanoparticle vectors are essential for achieving intended gene editing in the cornea.

Gene targeting by homologous recombination has been the gold standard for generating germ-line targeted gene knockout and knock-in mice[12,13]. Ocular cells represent a unique platform to investigate emerging technologies to gain an insight in to the precise molecular mechanisms underlying the disease as well as to develop novel personalized therapeutic strategies. According to clinicaltrials.gov there are currently multiple clinical studies on gene therapy and stem cell based regenerative medicine for ocular diseases. However, gene-targeting strategies in human embryonic stem (hES) and human induced pluripotent stem (hiPS) cells are relatively more cumbersome, inefficient, time consuming, expensive and challenging[14]. As a result, several studies have utilized small interfering RNA and short hairpin RNA to knockdown multiple genes. There are several major caveats of this approach including non-specificity, off target effects, altered cellular physiology, toxicity and only a transient reduction in gene expression leading to an incomplete or partial knockdown effect[15–19]. To overcome these limitations, it is imperative to modify the host genome precisely. The recent advances in gene editing have led to a widespread enthusiasm and significant improvements in this direction. In this review, we describe the current and emerging tools for gene editing, and their potential applications in the treatment of ocular diseases.

ZINC FINGER NUCLEASES

Zinc finger nucleases (ZFNs)'s belong to the first generation of gene editing tools based on the pioneering work of Kim et al[20–23]. ZFNs are designer nucleases that combine the DNA binding domain of eukaryotic transcription factors-zinc finger proteins with the nuclease domain of the *FokI* restriction enzyme[24,25]. In ZFNs, tandem arrays of Cys2His2 zinc fingers provide DNA binding specificity through recognition of approximately 3 base pairs of the target DNA. The catalytic domain of *FokI* requires dimerization to cleave the DNA at the targeted site and two adjacent ZFNs to independently bind to a specific codon with correct orientation and spacing. ZFNs work by introducing site-specific DNA double strand breaks (DSB) at a predetermined genomic locus. The DSB introduced by ZFNs undergo repair in the eukaryotic cells by either homology directed repair (HDR) process or non-homologous end joining pathway (NHEJ)[26–28]. DNA repair by homologous recombination leads to preservation of the original DNA sequence in the targeted cells rendering them vulnerable to re-cutting by ZFNs. In contrast, NHEJ can potentially lead to random insertion or deletion of nucleotides at the target break site thereby causing permanent disruption of the original DNA sequence. Figure 1 shows schematic representation of ZFN technology.

A previous study by Urnov et al[29] has demonstrated that ZFNs designed against X-linked severe combined immune deficiency (SCID) mutation in the *IL2R* gamma gene yielded > 18% gene-modified human cells with about 7% cells exhibiting desired genetic mutation on both X chromosomes. It has been previously demonstrated that HIV-1 uses the co-receptor CCR5, a validated target for HIV therapy[30,31]. Surprisingly, allogeneic stem cell transplant of a naturally occurring homozygous CCR5 deletion mutant (CCR5 32/ 32) led to the

elimination of HIV-1 in a patient[32]. Despite the low frequency of naturally occurring CCR5 Δ32/ Δ32 mutation, researchers have successfully harnessed the potential of ZFNs to disrupt *CCR5* gene expression in hematopoietic stem and progenitor cells using a recombinant adenoviral vector encoding CCR5-specific ZFNs[33]. Recently, ZFNs have shown potential therapeutic benefits in clinical trials[34–36]. In a recent open-label phase I clinical study, HIV patient-derived autologous CD4 T cells were subjected to ZFN-mediated gene editing to render them resistant to HIV by knocking out *CCR5* gene[36].

While the promise and feasibility of ZFN technology for gene editing has been demonstrated, multiple challenges remain. For example, ZFNs are relatively difficult to generate and are very expensive. Additionally, ZFNs can be non-specific and may result in off-target cleavage leading to multiple DSBs, which in turn can cause chromosomal rearrangements. These issues were addressed by developing ZFN variants that have ability to reduce off-target non-specific mutagenesis. The ZFN variants include a mix of two distinct ZFNs with different *FokI* domains that are obligate heterodimers, which introduce DSBs only when two distinct ZFNs are able to bind adjacent DNA regions[37–39].

TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES

Another approach to administer gene editing has subsequently emerged through the recognition of a new class of designer nucleases termed transcription activator-like effector nucleases (TALENS). The gene editing steps associated with TALEN technology are presented in Figure 2. Transcription activator-like effectors (TALEs) are proteins secreted by *Xanthomonas* bacteria to subvert the host genome regulatory networks and can be engineered to bind any desired target sequence[40–43]. TALEs have a DNA binding module termed TAL repeat, which is used by each protein in a tandem array with 10–30 repeats to recognize extended DNA sequences with a ratio of 1 TAL repeat to 1 base pair of DNA sequence[43]. Each repeat in turn has about 33–35 amino acids with 2 adjacent amino acids [Repeat Variable Di-residue (RVD)], which confer their specificity for the DNA bases[40,44]. Decoding of the RVD has led to the development of a new class of designer nucleases called TALENs that contain an array of TAL repeats fused to *FokI* nuclease domain[45–47].

As compared to ZFNs, TALENS are relatively easier to design and generate due to their modular nature[48]. The promise of TALEN approach has been successfully demonstrated through the generation of gene-knockout animal models of *C. elegans*, rats, mice and zebra fish[49–53]. Deml *et al*[53] have developed zebrafish mutants carrying *MAB21L2* gene to model human ocular coloboma. Homozygous *mab21l2^Q48Sfs*5* zebrafish mutant embryos exhibit severe lens and retinal defects with complete lethality while *mab21l2^R51_F52del* mutants display a milder lens phenotype and severe coloboma. This study demonstrates the power of genome editing in model organisms for studying molecular mechanisms underlying human ocular diseases. TALENs have recently been exploited to develop genetically engineered hES cell lines, hiPS cells and mouse disease models[45,54–57]. Experimental correction of genetic defects *in vitro* has been successfully achieved by TALENS in hemophilia[54], mitochondrial diseases[58,59], and Duchenne muscular dystrophy[60]. To demonstrate the potential utility and efficiency of TALENs, Ding *et al*[61] have successfully generated mutant alleles of 15 genes in cultured somatic cells or human

pluripotent stem cells. In an interesting study, Kim and colleagues have generated a library of 18740 TALEN pairs (http://www.talenlibrary.net/) to disrupt or modify every protein-coding gene for the entire human genome using a high throughput Golden-Gate cloning system[62]. In another study, Menon et al[63] utilized iPS cell technology and TALENs to generate a subject-specific mutant gene-corrected iPS cell lines for the treatment of X-linked SCID. It is interesting to note that while the subject derived mutant iPS cells could generate hematopoietic precursors and myeloid cells, only wild-type and gene corrected iPS cells could additionally generate mature cells and T cell precursors expressing the correctly spliced IL2R gamma. The work also suggests that TALEN technology can be employed for the manipulation of immune processes and chronic inflammatory diseases in the eye including corneal inflammatory disorders and diabetic retinopathy. Indeed, scores of further studies are needed to harness the bench-to-bedside potential of this approach and move forward towards the development of an autologous patient-based cell therapy.

The reversal of malignant phenotype *via* TALEN technology has been recently reported. Hu et al[64] have demonstrated that genome editing of human papilloma virus (HPV) oncogenes E6/E7 by TALENs efficiently reduced viral DNA load, restored the function of tumor suppressor p53/RB1, and reversed the malignant phenotype of host cells both *in vitro* as well as *in vivo*. In this study, HPV E6/E7 specific TALENs were effective in inducing apoptosis, inhibiting growth and reducing tumorigenicity in HPV positive cell lines. Further, direct cervical application of HPV E7 targeted TALENs efficiently mutated the E7 oncogene and reversed the malignant phenotype in K14-HPV16 transgenic mice. The study suggested two possible mechanisms for the reversal of the malignant phenotype. Firstly, TALENs specifically recognized and cleaved HPV DNA sequence in host cells leading to DSBs that directly induced apoptosis and suppressed their proliferation. Secondly, the cells that survived genotoxic stress, activated DSB repair *via* NHEJ pathway causing E6/E7 mutation. This led to the activation of E6/E7-inhibited tumor suppressor p53/RB1 and downregulation of CDK2 and E2F1. The ongoing experiments in our laboratory are attempting to generate *in vitro* and *in vivo* models and newer therapeutic approaches for corneal disorders and dystrophies using TALEN technology. This powerful gene editing approach has been particularly useful in studying keratoconus and Fuchs' endothelial corneal dystrophy.

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS AND CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT ASSOCIATED SYSTEMS

Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Clustered Regularly Interspaced Short Palindromic Repeat Associated Systems (Cas9), derived from the bacterial adaptive immune system, has tremendous potential for achieving precise *in vitro* and *in vivo* gene editing[65–69]. Figure 3 depicts the core principle of this approach for obtaining intended gene editing in the genome. For the sake of convenience, Figure 4 provides a side-by-side comparison between TALENs and CRISPR/Cas9 systems. CRISPR/Cas9 based gene editing relies on co-expression of the bacterial Cas9 endonuclease and a short guide RNA (sgRNA) sequence to generate DNA DSBs in eukaryotic cells. The excision occurs at genomic sites that have a short homologous sequence to the 5' end of the sgRNA

followed by an NGG sequence called protospacer-adjacent motif (PAM)[66,70]. Since DNA DSB are primarily repaired through the error-prone NHEJ pathway in eukaryotes *via* small indels generated at the target sites. Therefore, CRISPR/Cas9 system provides a simple and cost-effective approach to simultaneously disrupt the open reading frames of multiple coding genes to produce loss/gain of function alleles at a high versatility[71–78]. CRISPR/Cas9 system has been successfully used for genome editing in *C. elegans*, Drosophila, mosquito, zebrafish, mouse, rat and human[79–90]. Cas9 nucleases cleave the double stranded DNA through the activity of their RuvC and HNH nuclease domains to generate DSBs. Cas9 can be engineered to cut only one strand of the DNA by catalytically inactivating either the RuvC or HNH nuclease domains[66,91,92]. These newly designed Cas9 nickases offer a unique approach to gene editing with high fidelity and specificity.

Recently, Chen *et al*[93] have successfully combined tamoxifen-inducible CRISPR/Cas-mediated genome editing with Flp/FRT and Cre/LoxP system to generate inducible gene knockout hPSC lines. They found that targeting dual sgRNA was essential for biallelic knockin of FRT sequences to flank the exon. They further developed a strategy to simultaneously insert an activity controlled recombinase-expressing cassette and removed the drug-resistance gene thereby enhancing the generation of *SOX2, PAX6, OTX2* and *AGO2* inducible knockout human ES and iPS cell lines. The target genes in these cell lines can be uniformly deleted at any given time by simple application of 4-OHT.

Wu *et al*[94] have recently reported successful correction of *Crygc* gene mutation that causes cataracts in mice. In this study, a dominant mutation in *Crygc* gene could be rescued in mouse zygotes by co-injection of Cas9 mRNA and a sgRNA targeting the mutant allele. Correction in the *Crygc* gene occurred by HDR based on an exogenously supplied oligonucleotide or the endogenous wild type allele, with only rare evidence of off-target modifications. The resulting mice were fertile and were able to transmit the corrected allele to their progeny. Similarly, Courtney *et al*[95] have examined the potential of an allele-specific CRISPR/Cas9 system for hereditary corneal dystrophies by specifically focusing on a dominant-negative mutation in KRT12, Leu132Pro which results in Meesmann's epithelial corneal dystrophy. Further, Zhong *et al*[96] have utilized the CRISPR/Cas9 system to generate *Kcnj*13 mutant mice, which mimic human *KCNJ*13-related Leber congenital amaurosis, an early form of blindness.

The studies discussed above provide proof of principle for the application of CRISPR/Cas9 system in developing models of corneal dystrophies and personalized therapeutics for treating ocular diseases.

GENE EDITING FOR CORNEAL DISEASE MANAGEMENT

Cornea is an ideal target tissue for the development of personalized therapy. Gene editing approaches can successfully be used to develop novel corneal disease models. For example, it is possible to develop disease in a dish model for corneal dystrophies using patient derived corneal tissues. However, there are multiple challenges that need to be overcome before gene editing for corneal disease management becomes a reality. One of the major challenges is the lack of an authentic *in vitro* corneal endothelial cell culture model. This

is because feline and human corneal endothelial cells are extremely difficult to culture. To overcome this major limitation, we have recently established reversibly immortalized feline and human corneal endothelial cell lines using Doxycycline inducible lentiviral vector system expressing human papillomavirus E6/E7 chimeric gene product. These immortalized feline and human corneal endothelial cell lines are valuable to study pathophysiology as well as molecular mechanisms regulating dystrophies and wound healing in the cornea. Currently there is no *in vivo* model for Fuchs' endothelial corneal dystrophy.

We are attempting to develop novel Fuchs' endothelial corneal dystrophy models employing CRISPR/Cas9 gene editing technology and conditionally immortalized corneal endothelial cells (Figure 5). Further, gene editing can be used on patient derived iPS cells to develop novel corneal disease models. Gene editing can be used to treat corneal fibrosis and neovascularization by targeting pathologic genes, microRNAs, long noncoding RNAs, and/or signaling pathways driving corneal wound repair. Combat related traumatic corneal injuries present an ideal target where gene editing can be applied to maximize wound healing and tissue regeneration in corneal tissue without major adverse effects. Viral vectors and nanoparticles offer a novel platform to accomplish gene editing in corneal tissue. Real-time noninvasive intravital imaging will allow precise monitoring of gene editing success in an *in vivo* experimental animal model. Overall, there is tremendous potential of gene editing technology for corneal disease management as depicted in Table 1.

CURRENT CHALLENGES AND FUTURE DIRECTIONS

The current major limitations in the field of gene editing include concerns regarding specificity, efficiency, and delivery of designer nucleases (ZFNs, TALENs and CRISPR/Cas9). The non-viral delivery systems including electroporation and protein transfection of designer nucleases have shown promising results with limited applications. The cell-specific delivery of designer nucleases such as CRISPR/Cas9 could be achieved through the recombinant viral vectors including adeno-associated virus (rAAV), integrase deficient lentivirus, baculovirus, adenovirus or nanoparticle vectors. Our laboratory has successfully identified rAAV, disabled lentivirus and nanoparticle vectors for delivering therapeutic genes into keratocytes of the mouse and rabbit corneas *in vivo* and human and canine corneas using *ex vivo* organ culture models[4,97]. The restricted cloning capacity and challenges associated with packaging of the expression cassettes limit the use of current hybrid rAAV vectors. However, recently two different promising strategies have been successfully employed to overcome the packaging limitations of rAAV. A strategy developed by a commercial vendor, proposed that *Cas9* gene could be split between pAAV-Guide-it-Up and pAAV-Guide-it-Down plasmids with 1.6 kb region of homology. In this system, sgRNA sequence against the genomic sequence of interest could be cloned into pAAV-Guide-it-Down plasmid and two separate recombinant AAVs (AAV-Up and AAV-Down) could be generated and co-transduced into target cells. Due to precise homologous recombination at the site of homology, full-length Cas9 gene driven by an upstream promoter is generated in the targeted cells leading to successful genome editing. Employing a different strategy, Ran *et al*[98] have recently identified six smaller Cas9 orthologs. These authors showed that Cas9 from *Staphylococcus aureus* (SaCas9) could edit the genome with efficiencies similar to those of *Staphylococcus pyogenes* (SpCas9) despite being more than 1 kilobase shorter[98].

In these studies SaCas9 and its sgRNA expression cassette were packaged into hepatocyte tropic rAAV8 to target the cholesterol regulatory gene pro-protein convertase subtilisin/kexin type 9 (*Pcsk9*) in the mouse liver. Following systemic delivery with rAAV, > 40% genome modification accompanied by significant reduction in serum *Pcsk9* and total cholesterol levels was observed. Further, the specificity of SaCas9 was confirmed using an unbiased DSB detection method, BLESS to identify a list of candidate off-target cleavage sites. These studies highlight the potential of newer SaCas9 for AAV-mediated *in vivo* genome editing applications.

The possibility of undesired genetic modification is a major concern associated with current gene editing technologies. To minimize off-target activity of Cas9, Ran *et al*[99] have recently developed an approach that simultaneously combines a Cas9 nickase mutant with paired guide RNAs to introduce targeted DSB. Since individual nicks in the genome are repaired with high fidelity, simultaneous nicking *via* appropriately offset guide RNAs is required for DSB and extends the number of specifically recognized bases for target cleavage. This versatile strategy can reduce off target effects by 50- to 1500-fold in cell lines and therefore has a great potential for genome editing applications that require high fidelity as well as high specificity.

In yet another interesting study, Suzuki *et al*[100] have performed whole genome sequencing to evaluate the mutational load at single base resolution in individual gene-corrected hiPS cells derived from Hutchinson-Gilford progeria syndrome, sickle disease and Parkinson's disease patients. They have reported that in single cell clones, gene correction by helper-dependent adenoviral vector (HDAdV) or TALEN exhibited few off-target effects and a low level of sequence variation. Furthermore, they have developed a TALEN-HDAdV hybrid vector, which significantly increased gene-correction efficiency in hiPS cells. Interestingly, a comparative analysis of TALENs, CRISPR/Cas9 and HDAdV revealed that HDAdVs have a clear superiority over both CRISPR/Cas9 and TALENs in gene targeting and gene correction of the *HBB* locus.

Utilizing a novel approach, Nihongaki *et al*[101] have recently developed an engineered photoactivatable Cas9 (paCas9) that enables optogenetic control of CRISPR-Cas9 genome editing by NHEJ and HDR pathways in human cells. Optogenetic paCas9 was developed by fusing the two split Cas9 fragments with photoinducible dimerization domains termed magnets. The system gets activated in response to blue light and expresses paCas9 in target cells and induces targeted genome editing which can be switched off by extinguishing the light. Development of optogenetic paCas9 will enable conditional genome editing with ultra high precision and lead to potentially innovative gene and cellular therapies for currently incurable genetic disorders.

Most recently, Zetsche *et al*[102] have now characterized Cpf1, a new single crRNA-guided endonuclease which lacks tracrRNA and utilizes a T rich PAM. In contrast to the well-established Cas9, which requires tracrRNA to process crRNA arrays as well as crRNA and tracrRNA to mediate interference, Cpf1 doesn't require tracrRNA to process crRNA arrays. Furthermore, Cpf1-crRNA complexes are capable of independently cleaving target DNA molecules without any additional RNA species to generate staggered cut with a 5' overhang

unlike the blunt ends generated by Cas9. Additionally, Cpf1 has multiple advantages over Cas9 including smaller size and therefore it has a great potential to maximize high fidelity gene editing in corneal diseases.

Human germ line editing approach is currently in its infancy as its application has recently been demonstrated in China[103] and is gaining momentum in the United Kingdom. Further, CRISPR/Cas9 could be effectively used to eradicate selective group of harmful plants, animals or insects that interfere with the natural ecological balance. For example, taking a note of the fact that only female mosquitos (*Aedes aegypti*) which feed on blood are responsible for pathogenic transmission of dengue, yellow fever and chikungunya viruses, Hall *et al*[87] were able to harness the power of CRISPR/Cas9 system to knockout *Nix* gene leading to a population of largely feminized genetic males while induced ectopic expression of *Nix* resulted in genetic females with nearly complete male genitalia. This study represents a promising new approach for implementing vector-controlled strategies wherein the disease carrier female mosquitoes can be converted into harmless male mosquitoes.

Another, pressing challenge with viral vectors especially AAV and lentiviral vectors is that they have a broad tissue tropism and efficiently transduce vast majority of cell types both *in vitro* as well as *in vivo*[4]. As a result, targeted *in vivo* genome editing of a very specific cell type in a highly complex organ like eye is extremely challenging but not impossible. Several different approaches can be used either independently or in combination to circumnavigate and bypass this critical issue. First, a highly tissue specific promoter-enhancer combination can be used to specifically limit the expression of CRISPR-Cas9 to the desired cell type. However, tissue-specific promoters often times lack fidelity and exhibit promiscuous expression in non-targeted cells. Furthermore, transgene expression driven by tissue-specific promoters may either be inadequate for therapeutic effect or supra-physiological thereby leading to toxicity. Second approach involves either AAV capsid engineering or using a specific AAV serotype to target specific cell types. In this regard, doxycycline, rapamycin, mifepristone and tamoxifen inducible expression vectors offer an excellent choice. However, caution needs to be exercised since certain drugs like rapamycin can perturb endogenous mammalian target of rapamycin pathway. Alternatively, delivery of Cas9 vectors into the target cells using episomal expression vectors, integration deficient lentiviral vectors, adenoviral vectors and nanoparticles has a tremendous potential that needs to be explored. We believe that the development of novel hybrid genome editing vectors will lead to robust high fidelity targeted genome editing and will potentially enable futuristic gene and cellular therapies for currently incurable genetic disorders an ultimate reality.

The tremendous potential to achieve intended gene editing using ZFNs, TALENs and CRISPR/Cas9 system for the development of novel disease models and innovative therapies has been well demonstrated (Table 2). However, a theoretical risk remains that this technology can be misused and exploited for bioterrorism and may have unimaginable negative consequences. Thus, it is extremely important to develop stringent guidelines to prevent the potential misuse of CRISPR/Cas9 based innovative gene editing technology. Like any other genetic engineering technology ZFNs, TALENs, and CRISPR/Cas9 technologies can be a double-edged sword. Indeed, gene editing approach is going to play a

crucial role in improving human and animal health, increasing food and biopharmaceutical production, maintaining clean environment and revolutionizing medicine.

Acknowledgments

REFERENCES

1. Chaurasia SS, Lim RR, Lakshminarayanan R, Mohan RR. Nanomedicine approaches for corneal diseases. J Funct Biomater 2015; 6: 277–298 [DOI: 10.3390/jfb6020277] [PubMed: 25941990]

2. Burton MJ, Mabey DC. The global burden of trachoma: a review. PLoS Negl Trop Dis 2009; 3: e460 [DOI: 10.1371/journal.pntd.0000460] [PubMed: 19859534]

3. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ 2001; 79: 214–221 [PubMed: 11285665]

4. Mohan RR, Rodier JT, Sharma A. Corneal gene therapy: basic science and translational perspective. Ocul Surf 2013; 11: 150–164 [DOI: 10.1016/j.jtos.2012.10.004] [PubMed: 23838017]

5. Mohan RR, Schultz GS, Hong JW, Mohan RR, Wilson SE. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res 2003; 76: 373–383 [PubMed: 12573666]

6. Mohan RR, Sharma A, Cebulko TC, Tandon A. Vector delivery technique affects gene transfer in the cornea in vivo. Mol Vis 2010; 16: 2494–2501 [PubMed: 21139995]

7. Mohan RR, Sinha S, Tandon A, Gupta R, Tovey JC, Sharma A. Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea. PLoS One 2011; 6: e18771 [DOI: 10.1371/journal.pone.0018771] [PubMed: 21533273]

8. Mohan RR, Tandon A, Sharma A, Cowden JW, Tovey JC. Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy. Invest Ophthalmol Vis Sci 2011; 52: 4833–4841 [DOI: 10.1167/iovs.11-7357] [PubMed: 21551414]

9. Mohan RR, Tovey JC, Sharma A, Schultz GS, Cowden JW, Tandon A. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One 2011; 6: e26432 [DOI: 10.1371/journal.pone.0026432] [PubMed: 22039486]

10. Tandon A, Sharma A, Rodier JT, Klibanov AM, Rieger FG, Mohan RR. BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS One 2013; 8: e66434 [DOI: 10.1371/journal.pone.0066434] [PubMed: 23799103]

11. Sharma A, Tandon A, Tovey JC, Gupta R, Robertson JD, Fortune JA, Klibanov AM, Cowden JW, Rieger FG, Mohan RR. Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea. Nanomedicine 2011; 7: 505–513 [DOI: 10.1016/j.nano.2011.01.006] [PubMed: 21272669]

12. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 1985; 317: 230–234 [PubMed: 2995814]

13. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987; 51: 503–512 [PubMed: 2822260]

14. Vasquez KM, Marburger K, Intody Z, Wilson JH. Manipulating the mammalian genome by homologous recombination. Proc Natl Acad Sci USA 2001; 98: 8403–8410 [DOI: 10.1073/pnas.111009698] [PubMed: 11459982]

15. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635–637 [DOI: 10.1038/nbt831] [PubMed: 12754523]

16. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A. 3' UTR seed matches, but

not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3: 199–204 [DOI: 10.1038/nmeth854] [PubMed: 16489337]

17. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, Leake D, Marshall WS, Khvorova A. Off-target effects by siRNA can induce toxic phenotype. RNA 2006; 12: 1188–1196 [DOI: 10.1261/rna.28106] [PubMed: 16682561]

18. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009; 27: 549–555 [DOI: 10.1038/nbt.1543] [PubMed: 19465925]

19. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834–839 [DOI: 10.1038/ncb1038] [PubMed: 12942087]

20. Kim YG, Chandrasegaran S. Chimeric restriction endonuclease. Proc Natl Acad Sci USA 1994; 91: 883–887 [PubMed: 7905633]

21. Kim YG, Li L, Chandrasegaran S. Insertion and deletion mutants of FokI restriction endonuclease. J Biol Chem 1994; 269: 31978–31982 [PubMed: 7989374]

22. Kim SS, Chen YM, O'Leary E, Witzgall R, Vidal M, Bonventre JV. A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc Natl Acad Sci USA 1996; 93: 15299–15304 [PubMed: 8986806]

23. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 1996; 93: 1156–1160 [PubMed: 8577732]

24. Carroll D Genome engineering with targetable nucleases. Annu Rev Biochem 2014; 83: 409–439 [DOI: 10.1146/annurev-biochem-060713-035418] [PubMed: 24606144]

25. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11: 636–646 [DOI: 10.1038/nrg2842] [PubMed: 20717154]

26. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071–1078 [DOI: 10.1038/nature08467] [PubMed: 19847258]

27. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010; 11: 196–207 [DOI: 10.1038/nrm2851] [PubMed: 20177395]

28. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010; 79: 181–211 [DOI: 10.1146/annurev.biochem.052308.093131] [PubMed: 20192759]

29. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646–651 [DOI: 10.1038/nature03556] [PubMed: 15806097]

30. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661–666 [DOI: 10.1038/381661a0] [PubMed: 8649511]

31. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955–1958 [PubMed: 8658171]

32. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692–698 [DOI: 10.1056/NEJMoa0802905] [PubMed: 19213682]

33. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, Liu Q, Holmes MC, Cannon PM, Zaia JA, DiGiusto DL. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 2013; 21: 1259–1269 [DOI: 10.1038/mt.2013.65] [PubMed: 23587921]

34. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Human hematopoietic stem/progenitor cells modified by zinc-finger

nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28: 839–847 [DOI: 10.1038/nbt.1663] [PubMed: 20601939]

35. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26: 808–816 [DOI: 10.1038/nbt1410] [PubMed: 18587387]

36. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901–910 [DOI: 10.1056/NEJMoa1300662] [PubMed: 24597865]

37. Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, Miller JC, Urnov FD, Gregory PD, Holmes MC. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods 2011; 8: 74–79 [DOI: 10.1038/nmeth.1539] [PubMed: 21131970]

38. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007; 25: 778–785 [DOI: 10.1038/nbt1319] [PubMed: 17603475]

39. Szczepek M, Brondani V, Büchel J, Serrano L, Segal DJ, Cathomen T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol 2007; 25: 786–793 [DOI: 10.1038/nbt1317] [PubMed: 17603476]

40. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009; 326: 1509–1512 [DOI: 10.1126/science.1178811] [PubMed: 19933107]

41. Kay S, Hahn S, Marois E, Hause G, Bonas U. A bacterial effector acts as a plant transcription factor and induces a cell size regulator. Science 2007; 318: 648–651 [DOI: 10.1126/science.1144956] [PubMed: 17962565]

42. Römer P, Hahn S, Jordan T, Strauss T, Bonas U, Lahaye T. Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene. Science 2007; 318: 645–648 [DOI: 10.1126/science.1144958] [PubMed: 17962564]

43. Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science 2011; 333: 1843–1846 [DOI: 10.1126/science.1204094] [PubMed: 21960622]

44. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009; 326: 1501 [DOI: 10.1126/science.1178817] [PubMed: 19933106]

45. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng X, Hinkley SJ, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29: 731–734 [DOI: 10.1038/nbt.1927] [PubMed: 21738127]

46. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011; 29: 143–148 [DOI: 10.1038/nbt.1755] [PubMed: 21179091]

47. Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011; 29: 149–153 [DOI: 10.1038/nbt.1775] [PubMed: 21248753]

48. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012; 30: 460–465 [DOI: 10.1038/nbt.2170] [PubMed: 22484455]

49. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol 2011; 29: 699–700 [DOI: 10.1038/nbt.1939] [PubMed: 21822242]

50. Sander JD, Cade L, Khayter C, Reyon D, Peterson RT, Joung JK, Yeh JR. Targeted gene disruption in somatic zebrafish cells using engineered TALENS. Nat Biotechnol 2011; 29: 697–698 [DOI: 10.1038/nbt.1934] [PubMed: 21822241]

51. Tesson L, Usal C, Ménoret S, Leung E, Niles BJ, Remy S, Santiago Y, Vincent AI, Meng X, Zhang L, Gregory PD, Anegon I, Cost GJ. Knockout rats generated by embryo microinjection of TALENS. Nat Biotechnol 2011; 29: 695–696 [DOI: 10.1038/nbt.1940] [PubMed: 21822240]

52. Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R, Miller JC, Leung E, Meng X, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Meyer BJ. Targeted genome editing across species using ZFNs and TALENS. Science 2011; 333: 307 [DOI: 10.1126/science.1207773] [PubMed: 21700836]

53. Deml B, Kariminejad A, Borujerdi RH, Muheisen S, Reis LM, Semina EV. Mutations in MAB21L2 result in ocular Coloboma, microcornea and cataracts. PLoS Genet 2015; 11: e1005002 [DOI: 10.1371/journal.pgen.1005002] [PubMed: 25719200]

54. Park CY, Kim J, Kweon J, Son JS, Lee JS, Yoo JE, Cho SR, Kim JH, Kim JS, Kim DW. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci USA 2014; 111: 9253–9258 [DOI: 10.1073/pnas.1323941111] [PubMed: 24927536]

55. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, Chang JC, Bao G, Muench MO, Yu J, Levy JA, Kan YW. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5 32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 2014; 111: 9591–9596 [DOI: 10.1073/pnas.1407473111] [PubMed: 24927590]

56. Low BE, Krebs MP, Joung JK, Tsai SQ, Nishina PM, Wiles MV. Correction of the Crb1rd8 allele and retinal phenotype in C57BL/6N mice via TALEN-mediated homology-directed repair. Invest Ophthalmol Vis Sci 2014; 55: 387–395 [DOI: 10.1167/iovs.13-13278] [PubMed: 24346171]

57. Panda SK, Wefers B, Ortiz O, Floss T, Schmid B, Haass C, Wurst W, Kühn R. Highly efficient targeted mutagenesis in mice using TALENs. Genetics 2013; 195: 703–713 [DOI: 10.1534/genetics.113.156570] [PubMed: 23979585]

58. Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, Williams SL, Sugawara A, Okamura D, Tsunekawa Y, Wu J, Lam D, Xiong X, Montserrat N, Esteban CR, Liu GH, Sancho-Martinez I, Manau D, Civico S, Cardellach F, Del Mar O'Callaghan M, Campistol J, Zhao H, Campistol JM, Moraes CT, Izpisua Belmonte JC. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 2015; 161: 459–469 [DOI: 10.1016/j.cell.2015.03.051] [PubMed: 25910206]

59. Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 2013; 19: 1111–1113 [DOI: 10.1038/nm.3261] [PubMed: 23913125]

60. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, Hotta A. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 2015; 4: 143–154 [DOI: 10.1016/j.stemcr.2014.10.013] [PubMed: 25434822]

61. Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, Kuperwasser N, Motola DL, Meissner TB, Hendriks WT, Trevisan M, Gupta RM, Moisan A, Banks E, Friesen M, Schinzel RT, Xia F, Tang A, Xia Y, Figueroa E, Wann A, Ahfeldt T, Daheron L, Zhang F, Rubin LL, Peng LF, Chung RT, Musunuru K, Cowan CA. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12: 238–251 [DOI: 10.1016/j.stem.2012.11.011] [PubMed: 23246482]

62. Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJ, Kim S, Lee C, Jeong E, Chung E, Kim D, Lee MS, Go EM, Song HJ, Kim H, Cho N, Bang D, Kim S, Kim JS. A library of TAL effector nucleases spanning the human genome. Nat Biotechnol 2013; 31: 251–258 [DOI: 10.1038/nbt.2517] [PubMed: 23417094]

63. Menon T, Firth AL, Scripture-Adams DD, Galic Z, Qualls SJ, Gilmore WB, Ke E, Singer O, Anderson LS, Bornzin AR, Alexander IE, Zack JA, Verma IM. Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell 2015; 16: 367–372 [DOI: 10.1016/j.stem.2015.02.005] [PubMed: 25772073]

64. Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, Zhang C, Wang L, Ji T, Liu D, He D, Xia X, Zhu T, Wei J, Wu P, Wang C, Xi L, Gao Q, Chen G, Liu R, Li K, Li S, Wang S, Zhou J, Ma D, Wang H. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest 2015; 125: 425–436 [DOI: 10.1172/JCI78206] [PubMed: 25500889]

65. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819–823 [DOI: 10.1126/science.1231143] [PubMed: 23287718]

66. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816–821 [DOI: 10.1126/science.1225829] [PubMed: 22745249]

67. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 2013; 31: 833–838 [DOI: 10.1038/nbt.2675] [PubMed: 23907171]

68. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 2013; 10: 957–963 [DOI: 10.1038/nmeth.2649] [PubMed: 24076990]

69. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823–826 [DOI: 10.1126/science.1232033] [PubMed: 23287722]

70. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 2014; 507: 62–67 [DOI: 10.1038/nature13011] [PubMed: 24476820]

71. Sánchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 2015; 15: 387–395 [DOI: 10.1038/nrc3950] [PubMed: 26040603]

72. Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, Jacks T. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 2014; 516: 428–431 [DOI: 10.1038/nature13906] [PubMed: 25337879]

73. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 2015; 33: 102–106 [DOI: 10.1038/nbt.3055] [PubMed: 25326897]

74. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014; 343: 80–84 [DOI: 10.1126/science.1246981] [PubMed: 24336569]

75. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013; 153: 910–918 [DOI: 10.1016/j.cell.2013.04.025] [PubMed: 23643243]

76. Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y, Wei W. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 2014; 509: 487–491 [DOI: 10.1038/nature13166] [PubMed: 24717434]

77. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014; 343: 84–87 [DOI: 10.1126/science.1247005] [PubMed: 24336571]

78. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159: 440–455 [DOI: 10.1016/j.cell.2014.09.014] [PubMed: 25263330]

79. Yu Z, Ren M, Wang Z, Zhang B, Rong YS, Jiao R, Gao G. Highly efficient genome modifications mediated by CRISPR/Cas9 in Drosophila. Genetics 2013; 195: 289–291 [DOI: 10.1534/genetics.113.153825] [PubMed: 23833182]

80. Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods 2013; 10: 741–743 [DOI: 10.1038/nmeth.2532] [PubMed: 23817069]

81. Dickinson DJ, Ward JD, Reiner DJ, Goldstein B. Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nat Methods 2013; 10: 1028–1034 [DOI: 10.1038/nmeth.2641] [PubMed: 23995389]

82. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013; 31: 230–232 [DOI: 10.1038/nbt.2507] [PubMed: 23360966]

83. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013; 31: 227–229 [DOI: 10.1038/nbt.2501] [PubMed: 23360964]

84. Li D, Qiu Z, Shao Y, Chen Y, Guan Y, Liu M, Li Y, Gao N, Wang L, Lu X, Zhao Y, Liu M. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol 2013; 31: 681–683 [DOI: 10.1038/nbt.2661] [PubMed: 23929336]

85. Li W, Teng F, Li T, Zhou Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol 2013; 31: 684–686 [DOI: 10.1038/nbt.2652] [PubMed: 23929337]

86. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 2013; 154: 1370–1379 [DOI: 10.1016/j.cell.2013.08.022] [PubMed: 23992847]

87. Hall AB, Basu S, Jiang X, Qi Y, Timoshevskiy VA, Biedler JK, Sharakhova MV, Elahi R, Anderson MA, Chen XG, Sharakhov IV, Adelman ZN, Tu Z. SEX DETERMINATION. A male-determining factor in the mosquito Aedes aegypti. Science 2015; 348: 1268–1270 [DOI: 10.1126/science.aaa2850] [PubMed: 25999371]

88. Kistler KE, Vosshall LB, Matthews BJ. Genome engineering with CRISPR-Cas9 in the mosquito Aedes aegypti. Cell Rep 2015; 11: 51–60 [DOI: 10.1016/j.celrep.2015.03.009] [PubMed: 25818303]

89. Dong S, Lin J, Held NL, Clem RJ, Passarelli AL, Franz AW. Heritable CRISPR/Cas9-mediated genome editing in the yellow fever mosquito, Aedes aegypti. PLoS One 2015; 10: e0122353 [DOI: 10.1371/journal.pone.0122353] [PubMed: 25815482]

90. Basu S, Aryan A, Overcash JM, Samuel GH, Anderson MA, Dahlem TJ, Myles KM, Adelman ZN. Silencing of end-joining repair for efficient site-specific gene insertion after TALEN/CRISPR mutagenesis in Aedes aegypti. Proc Natl Acad Sci USA 2015; 112: 4038–4043 [DOI: 10.1073/pnas.1502370112] [PubMed: 25775608]

91. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012; 109: E2579–E2586 [DOI: 10.1073/pnas.1208507109] [PubMed: 22949671]

92. Sapranauskas R, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 2011; 39: 9275–9282 [DOI: 10.1093/nar/gkr606] [PubMed: 21813460]

93. Chen Y, Cao J, Xiong M, Petersen AJ, Dong Y, Tao Y, Huang CT, Du Z, Zhang SC. Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9. Cell Stem Cell 2015; 17: 233–244 [DOI: 10.1016/j.stem.2015.06.001] [PubMed: 26145478]

94. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, Yan Z, Li D, Li J. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013; 13: 659–662 [DOI: 10.1016/j.stem.2013.10.016] [PubMed: 24315440]

95. Courtney DG, Moore JE, Atkinson SD, Maurizi E, Allen EH, Pedrioli DM, McLean WH, Nesbit MA, Moore CB. CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. Gene Ther 2016; 23: 108–112 [DOI: 10.1038/gt.2015.82] [PubMed: 26289666]

96. Zhong H, Chen Y, Li Y, Chen R, Mardon G. CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes. Sci Rep 2015; 5: 8366 [DOI: 10.1038/srep08366] [PubMed: 25666713]

97. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog Retin Eye Res 2005; 24: 537–559 [DOI: 10.1016/j.preteyeres.2005.04.001] [PubMed: 15955719]

98. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520: 186–191 [DOI: 10.1038/nature14299] [PubMed: 25830891]

99. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013; 154: 1380–1389 [DOI: 10.1016/j.cell.2013.08.021] [PubMed: 23992846]

100. Suzuki K, Yu C, Qu J, Li M, Yao X, Yuan T, Goebl A, Tang S, Ren R, Aizawa E, Zhang F, Xu X, Soligalla RD, Chen F, Kim J, Kim NY, Liao HK, Benner C, Esteban CR, Jin Y, Liu GH, Li Y, Izpisua Belmonte JC. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 2014; 15: 31–36 [DOI: 10.1016/j.stem.2014.06.016] [PubMed: 24996168]

101. Nihongaki Y, Kawano F, Nakajima T, Sato M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol 2015; 33: 755–760 [DOI: 10.1038/nbt.3245] [PubMed: 26076431]

102. Zetsche B, Gootenberg Jonathan S, Abudayyeh Omar O, Slaymaker Ian M, Makarova Kira S, Essletzbichler P, Volz Sara E, Joung J, van der Oost J, Regev A, Koonin Eugene V, Zhang F. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell 2015; 163: 759–771 [DOI: 10.1016/j.cell.2015.09.038] [PubMed: 26422227]

103. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015; 6: 363–372 [DOI: 10.1007/s13238-015-0153-5] [PubMed: 25894090]

104. Chang CJ, Bouhassira EE. Zinc-finger nuclease-mediated correction of α-thalassemia in iPS cells. Blood 2012; 120: 3906–3914 [DOI: 10.1182/blood-2012-03-420703] [PubMed: 23002118]

105. Chen YG, Forsberg MH, Khaja S, Ciecko AE, Hessner MJ, Geurts AM. Gene targeting in NOD mouse embryos using zinc-finger nucleases. Diabetes 2014; 63: 68–74 [DOI: 10.2337/db13-0192] [PubMed: 23974926]

106. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18: 947–954 [DOI: 10.1038/mt.2010.20] [PubMed: 20160705]

107. Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood 2014; 123: 61–69 [DOI: 10.1182/blood-2013-08-521229] [PubMed: 24162716]

108. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298–1306 [DOI: 10.1038/nbt1353] [PubMed: 17965707]

109. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012; 18: 807–815 [DOI: 10.1038/nm.2700] [PubMed: 22466705]

110. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, Goodwin MJ, Hawkins JS, Ramirez CL, Batista LF, Artandi SE, Wernig M, Joung JK. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011; 29: 1717–1726 [DOI: 10.1002/stem.718] [PubMed: 21898685]

111. Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK, Chen G, Ye Z, Park IH, Daley GQ, Porteus MH, Joung JK, Cheng L. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5: 97–110 [DOI: 10.1016/j.stem.2009.05.023] [PubMed: 19540188]

112. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, Dowey SN, Cheng L, Malech HL. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011; 117: 5561–5572 [DOI: 10.1182/blood-2010-12-328161] [PubMed: 21411759]

113. Sharma R, Anguela XM, Doyon Y, Wechsler T, DeKelver RC, Sproul S, Paschon DE, Miller JC, Davidson RJ, Shivak D, Zhou S, Rieders J, Gregory PD, Holmes MC, Rebar EJ, High KA. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 2015; 126: 1777–1784 [DOI: 10.1182/blood-2014-12-615492] [PubMed: 26297739]

114. Chen W, Liu J, Zhang L, Xu H, Guo X, Deng S, Liu L, Yu D, Chen Y, Li Z. Generation of the SCN1A epilepsy mutation in hiPS cells using the TALEN technique. Sci Rep 2014; 4: 5404 [DOI: 10.1038/srep05404] [PubMed: 24953032]

115. Fadel HJ, Morrison JH, Saenz DT, Fuchs JR, Kvaratskhelia M, Ekker SC, Poeschla EM. TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol 2014; 88: 9704–9717 [DOI: 10.1128/JVI.01397-14] [PubMed: 24942577]

116. Huang X, Wang Y, Yan W, Smith C, Ye Z, Wang J, Gao Y, Mendelsohn L, Cheng L. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation. Stem Cells 2015; 33: 1470–1479 [DOI: 10.1002/stem.1969] [PubMed: 25702619]

117. Dreyer AK, Hoffmann D, Lachmann N, Ackermann M, Steinemann D, Timm B, Siler U, Reichenbach J, Grez M, Moritz T, Schambach A, Cathomen T. TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials 2015; 69: 191–200 [DOI: 10.1016/j.biomaterials.2015.07.057] [PubMed: 26295532]

118. Zhang S, Li L, Kendrick SL, Gerard RD, Zhu H. TALEN-mediated somatic mutagenesis in murine models of cancer. Cancer Res 2014; 74: 5311–5321 [DOI: 10.1158/0008-5472.CAN-14-0529] [PubMed: 25070752]

119. Park CY, Kim DH, Son JS, Sung JJ, Lee J, Bae S, Kim JH, Kim DW, Kim JS. Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. Cell Stem Cell 2015; 17: 213–220 [DOI: 10.1016/j.stem.2015.07.001] [PubMed: 26212079]

120. Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, Kong CW, Rushing S, Hansen J, Ceholski D, Kolokathis F, Kremastinos D, Katoulis A, Ren L, Cohen N, Gho JM, Tsiapras D, Vink A, Wu JC, Asselbergs FW, Li RA, Hulot JS, Kranias EG, Hajjar RJ. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 2015; 6: 6955 [DOI: 10.1038/ncomms7955] [PubMed: 25923014]

121. Ochiai H, Miyamoto T, Kanai A, Hosoba K, Sakuma T, Kudo Y, Asami K, Ogawa A, Watanabe A, Kajii T, Yamamoto T, Matsuura S. TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. Proc Natl Acad Sci USA 2014; 111: 1461–1466 [DOI: 10.1073/pnas.1317008111] [PubMed: 24344301]

122. Liu H, Chen Y, Niu Y, Zhang K, Kang Y, Ge W, Liu X, Zhao E, Wang C, Lin S, Jing B, Si C, Lin Q, Chen X, Lin H, Pu X, Wang Y, Qin B, Wang F, Wang H, Si W, Zhou J, Tan T, Li T, Ji S, Xue Z, Luo Y, Cheng L, Zhou Q, Li S, Sun YE, Ji W. TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. Cell Stem Cell 2014; 14: 323–328 [DOI: 10.1016/j.stem.2014.01.018] [PubMed: 24529597]

123. Wang H, Hu YC, Markoulaki S, Welstead GG, Cheng AW, Shivalila CS, Pyntikova T, Dadon DB, Voytas DF, Bogdanove AJ, Page DC, Jaenisch R. TALEN-mediated editing of the mouse Y chromosome. Nat Biotechnol 2013; 31: 530–532 [DOI: 10.1038/nbt.2595] [PubMed: 23666012]

124. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015; 6: 6244 [DOI: 10.1038/ncomms7244] [PubMed: 25692716]

125. Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi anemia gene editing by the CRISPR/Cas9 system. Hum Gene Ther 2015; 26: 114–126 [DOI: 10.1089/hum.2014.111] [PubMed: 25545896]

126. Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T, Sato T. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 2015; 21: 256–262 [DOI: 10.1038/nm.3802] [PubMed: 25706875]

127. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32: 551–553 [DOI: 10.1038/nbt.2884] [PubMed: 24681508]

128. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014; 514: 380–384 [DOI: 10.1038/nature13589] [PubMed: 25119044]

129. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 2014; 345: 1184–1188 [DOI: 10.1126/science.1254445] [PubMed: 25123483]

130. Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, Vrbanac V, Garrison BS, Stortchevoi A, Bryder D, Musunuru K, Brand H, Tager AM, Allen TM, Talkowski ME, Rossi DJ, Cowan CA. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014; 15: 643–652 [DOI: 10.1016/j.stem.2014.10.004] [PubMed: 25517468]

131. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EE, Beekman JM, Clevers H. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013; 13: 653–658 [DOI: 10.1016/j.stem.2013.11.002] [PubMed: 24315439]

132. Vinayak S, Pawlowic MC, Sateriale A, Brooks CF, Studstill CJ, Bar-Peled Y, Cipriano MJ, Striepen B. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 2015; 523: 477–480 [DOI: 10.1038/nature14651] [PubMed: 26176919]

133. Price AA, Sampson TR, Ratner HK, Grakoui A, Weiss DS. Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci USA 2015; 112: 6164–6169 [DOI: 10.1073/pnas.1422340112] [PubMed: 25918406]

Core tip:

Gene editing technology including Clustered Regularly Interspaced Short Palindromic Repeats/Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9, zinc finger nucleases, or transcription activator like effector nucleases has great potential for generating *in vitro* and *in vivo* models of corneal diseases including keratoconus and Fuchs' endothelial corneal dystrophy. Furthermore, gene editing is a powerful tool for studying molecular mechanisms mediating corneal development, pathogenesis and developing next generation innovative gene therapies including the patient-specific personalized medicine for curing corneal diseases. This review discusses current status and latest developments in the field of gene editing. Gene editing based molecular therapy has the potential to revolutionize current practices in ophthalmology clinic for curing corneal blindness.

Figure 1. Schematic diagram showing structure and design of a typical zinc finger nuclease.
Zinc finger nucleases (ZFNs) use a modular array of 3–6 ZFNs (4 shown) specifically designed to bind to the target DNA together with the FokI cleavage domain. The FokI cleavage domains can be engineered to function as heterodimers or homodimers to achieve desired cleavage specificity. ZFNs typically recognize 24–36 bp unique sequence within the genome to achieve target specificity. ZFN mediated cleavage of the target leads to double strand breaks, which in turn induces either non-homologous end joining pathway (NHEJ) or homology directed repair (HDR) processes. NHEJ leads to gene disruption due to small insertions or deletions (indels) while HDR leads to gene correction.

Figure 2. Transcription activator-like effector nucleases.

In transcription activator-like effector nucleases (TALENs) the nuclease effector domains of FokI are fused to TALE DNA binding domains. Since FokI is active only as a dimer, pair of TALENs are constructed to position FokI nuclease domains adjacent to genomic target sites. Like zinc finger nucleases, dimerization of TALENs leads to double strand breaks that is repaired by either error prone non-homologous end joining pathway thereby leading to frameshift mutations (deletions, insertions or frameshift) if exons are targeted or homology directed repair which can be utilized to introduce non-random mutations, targeted deletion or addition of large fragments.

Figure 3. Clustered Regularly Interspaced Short Palindromic Repeat/Clustered Regularly Interspaced Short Palindromic Repeat Associated Systems.

In contrast to Like zinc finger nucleases and transcription activator-like effector nucleases, Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated protein (Cas9) monomer possess innate nuclease activity which catalyzes double strand breaks leading to random knockout phenotypes *via* non-homologous end joining pathway. Therefore Cas9 requires a single guide RNA (sgRNA) to recognize its target site. The sgRNA is composed of two separately expressed RNAs including a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA), which are processed by endogenous bacterial machinery to yield the mature gRNA. The current CRISPR/Cas9 system employs a single chimeric sgRNA, which is a fusion of crRNA and tracrRNA. Currently used sgRNA typically contains a 17–20 nucleotide long variable region, which is complementary to the genomic target sequence. A short region immediately 3' to the target sequence known as protospacer adjacent motif has NGG sequence which is a major specificity determinant of Cas9. PAM: Protospacer-adjacent motif.

Figure 4. Venn diagram of transcription activator-like effector nucleases and Clustered Regularly Interspaced Short Palindromic Repeat.

The schematic Venn diagram shows potential differences and similarities between transcription activator-like effector nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) systems. The gold standard to decipher the gene function is to selectively knockout or disrupt the gene expression and analyze the resulting phenotypes. Both TALENs and CRISPR are promising and powerful gene editing tools that allow complete loss-of-function reverse genetics approaches to study gene function. sgRNA: Single guide RNA; Cas9: Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9.

Figure 5. Application of Clustered Regularly Interspaced Short Palindromic Repeat/Clustered Regularly Interspaced Short Palindromic Repeat Associated Systems to develop novel therapies for corneal diseases.

Corneal Delivery of Clustered Regularly Interspaced Short Palindromic Repeat/Clustered Regularly Interspaced Short Palindromic Repeat Associated System using recombinant adeno-associated virus, integrase deficient lentiviral vectors and nanovectors can be used to potentially target multiple corneal diseases especially Fuchs' endothelial corneal dystrophy to develop novel disease models as well as innovative personalized gene and stem cell therapies. PAM: Protospacer adjacent motif. Cas9: Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Application of gene editing for corneal disease management

Disease	Target genes for gene editing
Corneal fibrosis	BMP7, CTGF, Decorin, Hevin, Moesin, Smad2, Smad3, Smad4, Smad7, TGFβ1, TGFβR2, TRPA-1, Twist2, Vimentin
Corneal wound healing	CTGF, CNTF, EGF, EGFR1, EGFR2, Fibronectin, IGF, KGF, Laminin, Lumican, MIF, MMP-1, MMP-2, MMP-3, MMP-9, NGF, OGF, PAI-1, PAF, PDGF, rho-associated protein kinase (ROCK), TGFβ1, TGFβ2, TGFβ3, TLR4, TIMP-2, Vasohibin
Corneal neovascularization	Angiopoietin 1, Angiopoietin 2, Angiostatin, bFGF, Endostatin, FGFR-1, FGFR-2, FGFR-3, FGFR-4, FOXC1, HGF, IGF, IL-8, IL-1, Leptin, MMP-2, MMP-9, MMP-14, Netrin-1, Netrin-4, Neuropilin-2, NF-κB, PAI-1, PDGF, PEDF, PGF, Prox-1, ROCK, TNFα, TGFβ, TSP-1, Tie2, VCAM-1, VE-Cadherin, VEGF, VEGFR-1, VEGFR2, VEGFR-3
Keratoconus	BANP-ZNF469, LOX, BNIP3, CAST, CLF1, COL4A4, COL5A1, CPT1B, CPTB1B, DOCK9, IL-1A, IL-1B, IPO5, KRT72, MPDZ-NFIB, NEFL, Noxa, PMAIP1, RAB3GAP1, SLC25A2, SLC25A4, SLC25A31, SOD2, STK24, TGFB1, TIMP1, TIMP3, UCP1, UCP3, VSX1, ZEB1
Congenital hereditary endothelial dystrophy	SLC4A11
Epithelial basement membrane dystrophy	TGFBI
Francois-neetens mouchetee fleck corneal dystrophy	PIKFYVE (PIP5K3)
Fuchs' endothelial corneal dystrophy	APEX1, AGBL1, COL8A2, LOXHD1, NOX4, SLC4A11, SnaI1, TCF4, TCF8, ZEB1
Granular corneal dystrophy type 2	TGFBI, TGFBIp
Gelatinous drop-like corneal dystrophy	TACSTD2
Macular corneal dystrophy	CHST6
Meesmann epithelial corneal dystrophy	KRT3, KRT12
Posterior polymorphous corneal dystrophy	COL8A2, VSX1, ZEB1
Reis-Bücklers' and Thiel-Behnke Corneal dystrophies	TGFBI
Schnyder corneal dystrophy	UBIAD1

TGFβ1: Transforming growth factor beta 1; TGFβR1: Transforming growth factor btea receptor 2; EGF: Epidermal growth factor; MMP-1: Matrix metalloproteinase-1; TIMP-2: Tissue inhibitor of metalloproteinases metallopeptidase inhibitor 2; TLR4: Toll-like receptor 4; IL: Interleukin; NF-κB: Nuclear factor kappa B; TNFα: Tumor necrosis factor alpha.

Table 2

Potential applications of zinc finger nucleases, transcription activator-like effector nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Clustered Regularly Interspaced Short Palindromic Repeat Associated Systems to develop novel disease models and innovative therapeutic strategies

Target gene	Target cell	ZFN/TALEN/CRISPR	Disease	Ref.
α-Globin	Human iPS	ZFN	α-thalassemia	[104]
Tnfrsf9	NOD mouse embryo	ZFN	Diabetes	[105]
HBV	Huh cells	ZFN	Hepatitis B	[106]
CCR5, CXCR4	CD+ T cells	ZFN	HIV	[107]
CCR5, IL2RG	Multiple	ZFN	HIV, X-SCID	[108]
TCRα, β	T cells	ZFN	Leukemia	[109]
HBB	Human iPS cells	ZFN	Sickle cell anemia	[110]
PIG-A	Human ES, iPS cells	ZFN	PNH	[111]
gp91(phox)	Human iPS cells	ZFN	X-CGD	[112]
Albumin	Mouse hepatocytes	ZFN	Hemophilia A and B	[113]
SCN1A	Human iPS	TALEN	Epilepsy	[114]
PSIP1	HT080, 293T, Jurkat	TALEN	HIV	[115]
HBB	Human iPS cells	ZFN/TALEN/CRISPR	Sickle cell anemia	[116]
gp91(phox)	Human iPS cells	TALEN	X-CGD	[117]
Ctnnb1, Apc	H2.35	TALEN	Hepatocellular carcinoma	[118]
hFVIII	Human iPS cells	TALEN	Hemophilia A	[119]
PLN R14del	Human iPS cells	TALEN	Cardiomyopathy	[120]
BUB1B	HCT6	TALEN	PCS (MVA)	[121]
MECP2	Monkey zygotes	TALEN	Rett syndrome	[122]
Sry, Uty	Mouse blastocysts	TALEN	NA	[123]
Dystrophin	Myoblasts	CRISPR/Cas9	DMD	[124]
FANCC	Patient fibroblasts	CRISPR/Cas9	Fanconi anemia	[125]
APC, SMAD4, TP53, KRAS, PIK3CA	Human intestinal epithelial organoids	CRISPR/Cas9	Colorectal cancer	[126]
FAH	Mouse liver	CRISPR/Cas9	Tyrosinemia	[127]
PTEN, TP53	Mouse liver	CRISPR/Cas9	Liver cancer	[128]
DMD	Mdx mouse zygotes	CRISPR/Cas9	DMD	[129]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Target gene	Target cell	ZFN/TALEN/CRISPR	Disease	Ref.
B2M, CCR5	CD+ T and CD3+ HSC	CRISPR/Cas9	NA	[130]
CFTR	CF intestinal organoids	CRISPR/Cas9	Cystic Fibrosis	[131]
C. parvum	HCT8	CRISPR/Cas9	Cryptosporidiosis	[132]
HCV	Huh.5	FnCas9	Hepatitis C	[133]

ZFN: Zinc finger nuclease; TALEN: Transcription activator-like effector nucleases; CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats; Cas9: CRISPR associated protein 9; HIV: Human immunodeficiency virus; NOD: Non-obese diabetic.